Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 458,943 | 491,323 | 539,715 | 563,864 | 748,420 |
| Marketable Securities | 178,498 | 146,239 | 164,539 | 175,298 | 60,057 |
| TOTAL | $658,044 | $675,700 | $732,328 | $769,850 | $817,304 |
| Non-Current Assets | |||||
| PPE Net | 379 | 383 | 323 | 312 | 238 |
| Investments And Advances | 71,239 | 92,609 | 53,091 | 44,172 | 0 |
| Intangibles | 375 | 407 | 439 | 470 | 502 |
| Other Non-Current Assets | 2,606 | 185 | 246 | 308 | 369 |
| TOTAL | $74,599 | $93,584 | $54,099 | $45,262 | $1,109 |
| Total Assets | $732,643 | $769,284 | $786,427 | $815,112 | $818,413 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 8,090 | 8,970 | 3,632 | 5,895 | 6,087 |
| Accrued Expenses | 5,092 | 15,422 | 10,098 | 9,460 | 8,021 |
| Other current liabilities | 50,229 | 57,272 | 44,361 | 20,932 | 23,523 |
| TOTAL | $67,421 | $85,787 | $58,272 | $36,512 | $40,913 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 3,987 | 3,987 | N/A | N/A | 3,030 |
| Other Non-Current Liabilities | 0 | 66 | 85 | 103 | 137 |
| TOTAL | $N/A | $66 | $85 | $103 | $137 |
| Total Liabilities | $67,421 | $85,853 | $58,357 | $36,615 | $41,050 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 116,904 | 114,975 | 113,391 | 112,629 | 112,271 |
| Common Shares | 14,594 | 14,278 | 14,107 | 14,014 | 13,968 |
| Retained earnings | -810,831 | -762,390 | -687,467 | -615,462 | -598,098 |
| Other shareholders' equity | 4,221 | 4,793 | 4,640 | 4,327 | 4,434 |
| TOTAL | $665,222 | $683,431 | $728,070 | $778,497 | $777,363 |
| Total Liabilities And Equity | $732,643 | $769,284 | $786,427 | $815,112 | $818,413 |